Regeneron And Sanofi's Dupixent Becomes First Biologic To Achieve Significant Improvements In Disease Remission In Bullous Pemphigoid Trial
Portfolio Pulse from Benzinga Newsdesk
Regeneron and Sanofi's Dupixent has shown significant improvements in disease remission for bullous pemphigoid, meeting all primary and secondary endpoints in a trial. If approved, it would be the first targeted treatment for this condition in the U.S. and EU.
September 11, 2024 | 5:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron's Dupixent has achieved significant trial results for bullous pemphigoid, potentially becoming the first targeted treatment for this condition in the U.S. and EU.
The successful trial results for Dupixent in treating bullous pemphigoid could lead to its approval as the first targeted treatment for this condition, positively impacting Regeneron's stock.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Sanofi's Dupixent has shown significant trial success in treating bullous pemphigoid, potentially becoming the first targeted treatment for this condition in the U.S. and EU.
The positive trial results for Dupixent in bullous pemphigoid could lead to its approval, enhancing Sanofi's product portfolio and positively impacting its stock.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90